skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Transdermal hormone therapy and bone health

Review

(2376) Views  (441) Full article downloads

Authors: Lee P Shulman

Published Date March 2008 Volume 2008:3(1) Pages 51 - 54
DOI: http://dx.doi.org/10.2147/CIA.S937

Lee P Shulman

Division of Reproductive Genetics, Department of Obstetrics and Gynecology, Feinberg School of Medicine of Northwestern University, Chicago, Illinois, USA

Abstract: The clinical aftermath of the reporting of the initial findings of the Women’s Health Initiative (WHI) in 2002 was a profound reduction in the use of hormone therapies by menopausal women. This reduction led to a well documented increase in vasomotor symptoms and vaginal atrophy among those women who discontinued their hormone regimens. However, another adverse impact among these women, as well as many other menopausal women, is the well recognized increased likelihood of osteoporosis resulting from the decline in circulating estradiol levels associated with natural and surgical menopause. Although the use of non-hormonal drugs such as bisphosphonates has been shown to reduce the risk of fracture in women with osteoporosis, bisphosphonates have not been shown to reduce the risk of fracture in non-osteoporotic women. Indeed, only oral estrogen (as demonstrated in the WHI studies) has been shown to reduce the risk of fracture in osteoporotic and non-osteoporotic women. As non-oral hormone therapies have been shown to be as effective in treating vasomotor symptoms and vulvovaginal atrophy and to have a different (and perhaps more beneficial) physiological effect than oral regimens, it behooves us to assess the impact of non-oral hormone regimens on bone mineral density and fracture risk. Although there are no clinical trials that primarily assess the impact of non-oral regimens on fracture risk in menopausal women, numerous studies are consistent in demonstrating the positive impact of non-oral regimens in maintaining and increasing bone mineral density among users, even for those women using estrogen doses that are considered to be “too low” to have a beneficial impact on other menopausal symptoms.

Keywords: menopause, hormone, estrogen, non-oral, bone, osteoporosis, fracture








Readers of this article also read:

A review of tazarotene in the treatment of photodamaged skin
Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence
The influence of nano MgO and BaSO4 particle size additives on properties of PMMA bone cement
White versus gray matter function as seen on neuropsychological testing following bone marrow transplant for acute leukemia in childhood
Differences between the bisphosphonates for the prevention and treatment of osteoporosis
Use of ibandronate in the prevention of skeletal events in metastatic breast cancer
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
Erratum
If you don't take it – it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy